초록 ▼

The present invention relates to uses of cucurbitacins and compositions comprising cucurbitacin B. The present invention also relates to methods for preventing or treating various diseases and disorders by administering to a subject in need thereof cucurbitacin B. The invention also encompass method

The present invention relates to uses of cucurbitacins and compositions comprising cucurbitacin B. The present invention also relates to methods for preventing or treating various diseases and disorders by administering to a subject in need thereof cucurbitacin B. The invention also encompass methods of developing a therapeutic that comprises a cucurbitacin using the signaling molecules in the Ras-Raf-Mek-Elk-STAT3 pathway.

대표청구항 ▼

What is claimed is: 1. A method for inhibiting growth of cancer cells in a subject, comprising: modulating at least one signaling molecule selected from the group consisting of Raf, Mek1, Mek2, Erk1, Erk2 and STAT3 by administering an effective amount of an isolated cucurbitacin to said subject.

What is claimed is: 1. A method for inhibiting growth of cancer cells in a subject, comprising: modulating at least one signaling molecule selected from the group consisting of Raf, Mek1, Mek2, Erk1, Erk2 and STAT3 by administering an effective amount of an isolated cucurbitacin to said subject. 2. The method of claim 1, wherein said cucurbitacin comprises cucurbitacin B, and wherein said administering an effective amount comprises contacting said cancer cells with cucurbitacin B at a concentration of 15.6 nM to 35.3 nM. 3. The method of claim 1, wherein said cancer cells are leukemia cancer cells. 4. A method for inhibiting a signal transduction pathway in cancer cells in a subject, comprising: modulating at least one signaling molecule selected from the group consisting of Raf, Mek1, Mek2, Erk1, Erk2 and STAT3 by administering an effective amount of an isolated cucurbitacin to said subject. 5. The method of claim 4, wherein said cucurbitacin comprises cucurbitacin B, and wherein said administering an effective amount comprises contacting said cancer cells with cucurbitacin B at a concentration of 1 μM to 50 μM. 6. The method of claim 4, wherein said signal transduction pathway comprises a Raf/Mek/Erk pathway. 7. The method of claim 6, wherein said signaling molecule comprises STAT3. 8. The method of claim 6, wherein said cancer cells are leukemia cancer cells. 9. A method for inducing cell cycle arrest on cancer cells in a subject, comprising: modulating at least one a signaling molecule selected from the group consisting of Raf, Mek1, Mek2, Erk1, Erk2 and STAT3 by administering an effective amount of an isolated cucurbitacin to said subject. 10. The method of claim 9, wherein said cucurbitacin comprises cucurbitacin B, and wherein said administering an effective amount comprises contacting said cancer cells with cucurbitacin B at a concentration of 5 nM to 80 nM. 11. The method of claim 10, wherein said cancer cells decrease in G1/S phase when contacted with cucurbitacin B at a concentration of 40 nM to 80 nM. 12. The method of claim 10, wherein said cancer cells increase in G2/M phase when contacted with cucurbitacin B at a concentration of 40 nM to 80 nM. 13. The method of claim 9, wherein said cancer cells are leukemia cancer cells. 14. A method for inducing apoptosis in cancer cells in a subject, comprising: modulating at least one signaling molecule selected from the group consisting of Raf, Mek1, Mek2, Erk1, Erk2 and STAT3 by administering an effective amount of an isolated cucurbitacin to said subject. 15. The method of claim 14, wherein said cucurbitacin comprises cucurbitacin B, and wherein said administering an effective amount comprises contacting said cancer cells with cucurbitacin B at a concentration of 5 nM to 80 nM. 16. The method of claim 14, wherein said cancer cells increase in size when contacted with cucurbitacin at a concentration of 20 nM to 40 nM. 17. The method of claim 14, wherein said cancer cells decrease in size when contacted with cucurbitacin at a concentration of at least 80 nM. 18. The method of claim 14, wherein said cancer cells are leukemia cancer cells.